Mubasher: UK-based LUNAC Therapeutics, along with the Medicines Discovery Catapult and the University of Leeds, has been awarded a GBP 3.14 million funding under Innovate UK’s Biomedical Catalyst programme.
The funding will be directed to the development of a new anticoagulant treatment with limited bleeding risk, according to a statement on Monday.
LUNAC, the University of Leeds, and the Medicines Discovery Catapult “will work together to optimise and advance the discovery of a new class of highly specific anticoagulant compounds that block an activated clotting enzyme, Factor XII (FXIIa), for which there is strong evidence that inhibition will not increase the risk of bleeding.”
Current anticoagulant treatments have higher risks of bleeding that could be fatal at times.
New anticoagulants are expected to save more than GBP 2.7 billion annually, by reducing bleeding and stroke risks in Europe alone.